CG Oncology aims for $209M IPO, as more biotechs eye path to public markets

CG Oncology is hoping to raise $209 million from its upcoming IPO, blazing a trail to the public markets that seems to be enticing more biotechs in the first month of the year.

Bladder cancer-focused CG kicked off 2024 by outlining plans to go public, although the company didn’t offer any figures at the time. Now, the biotech has said it is looking to sell 11.8 million shares at a price of between $16 and $18 apiece.